BACKGROUND: Inhaled @entity5023 (FP) is a high potency inhaled corticosteroid used in the treatment of @entity565 . OBJECTIVES: 1. To assess the efficacy and safety outcomes in studies that compared inhaled @entity5023 at different nominal daily doses in the treatment of @entity102 . 2. To test for the presence of a dose response effect. SEARCH STRATEGY: We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999). SELECTION CRITERIA: Randomised trials in @entity1 and adults comparing @entity5023 at different nominal daily doses in the treatment of @entity102 . Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One reviewer extracted data. Quantitative analyses where undertaken using Review Manager 4.0.3 with Metaview 3.1. MAIN RESULTS: 20 studies (>6000 @entity1 ) met the inclusion criteria. Methodological quality was high. In non-oral @entity134 treated asthmatics with mild-moderate disease, a dose response effect was present for morning PEF; when comparing low doses (200 vs 100 mcg/d) @entity353 ( @entity353 ) 6 L/min, 95% Confidence Interval (CI) 1, 10 L/min; medium-low dose (400-500 vs 100 mcg/d), @entity353 8 L/min, 95%CI 1,15 L/min); and high vs low dose (800-1000 vs 50-100 mcg/d), @entity353 22 L/min 95% CI 15,29 L/min). There was no dose response in symptoms or rescue @entity2263 agonist use. @entity5253 was significantly higher with 800-1000 mcg/d than 50-100 mcg/d. In oral @entity134 dependent disease gain 2000 mcg/d had a greater effect than 1000-1500 mcg/d in likelihood of stopping @entity617 (Peto Odds Ratio 2.8, 95% CI 1.3, 6.3) and reduced daily @entity617 dose ( @entity353 2.0 mg/d, 95% CI 0.1, 4.0 mg/d). REVIEWER'S CONCLUSIONS: Effects of @entity5023 are dose dependent but relatively small. @entity1 with mild to moderate disease achieve similar levels of @entity565 control on low doses of @entity5023 (200 mcg/d or less) as they do on high doses (500 mcg/d or greater). In oral corticosteroid dependent asthmatics, reductions in @entity617 requirement may be gained with FP 2000 mcg/d.

Inhaled @entity5023 at different doses for XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients'] @entity5253 :: ('MESH:D002180', 'Disease') :: ['Hoarseness and oral Candidiasis'] @entity353 :: ('MESH:D015431', 'Disease') :: ['Weighted Mean Difference', 'WMD'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic asthma'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity2263 :: ('10242', 'Gene') :: ['beta2'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate', 'fluticasone'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity102 :: (MESH:D002908,Disease) :: ['chronic asthma']
